vimarsana.com

உலகளாவிய ஆண்டிமைக்ரோபியல் எதிர்ப்பு கண்டுபிடிப்பு நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Most vulnerable set to benefit from further £1 million investment to safeguard modern medicine | Department of Health and Social Care

SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic

SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic on May 11 2021 6:00 AM Test will detect infection of chlamydia and gonorrhoea and determine antimicrobial susceptibility to easy-to-access antibiotics within 60 minutes SYDNEY (BUSINESS WIRE) #AntimicrobialStewardship SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria. SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones. Funds will be used to develop a rapid test for the combined detection of

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.